Frequency of Different Precipitating Factors of Hepatic Encephalopathy in Patients with Cirrhosis of Liver Based on Child Class

Size: px
Start display at page:

Download "Frequency of Different Precipitating Factors of Hepatic Encephalopathy in Patients with Cirrhosis of Liver Based on Child Class"

Transcription

1 ORIGINAL ARTICLE Frequency of Different Precipitating Factors of Hepatic Encephalopathy in Patients with Cirrhosis of Liver Based on Child Class Wajid Hussain 1, Atif Abbas 2, Ayesha Isani Majeed 3, Muhammad Umer 4, Alishba Mukhtar 5, Aamir Afzal 6 A u t h o r ` s A f f i l i a t i o n 1,2,4,5 Medical specialist Fauji Foundation Hospital, Rawalpindi Foundation University Medical College, Rawalpindi 3 Associate Professor of Radiology Pims, Szabmu, Ph.D. Scholar, Health Services Academy, Quaid -e- Azam University, Islamabad 6 Bio Statistician, Fauji Foundation Hospital, Rawalpindi A u t h o r ` s C o n t r i b u t i o n 1,2,4,5 Conception, synthesis, planning of research, 3 Active participation in active Methodology, 6 Data Analysis A r t i c l e I n f o Received: June 25, 2017 Accepted: Sept 16, 2017 H o w to C i t e t h i s M a n u s c r i p t Hussain W, Abbas A, Majeed AI, Umer M, Mukhtar A, Afzal A. Frequency of Different Precipitating Factors of Hepatic Encephalopathy in Patients with Cirrhosis of Liver Based on Child Class. Ann. Pak. Inst. Med. Sci. 2017; 13(3): Funding Source: Nil Conflict of Interest: Nil Address of Correspondence Dr. Wajid Hussain doc_wajid5@hotmail.com A B S T R A C T Objective: To determine the frequency of precipitating factors of Hepatic Encephalopathy in Patients with Cirrhosis of Liver based on Child class. Study Design: Descriptive study. Setup: Medical Unit of Fauji Foundation Hospital (FFH) Rawalpindi. Duration of study: Duration of study was 06 months after the approval of synopsis i.e 1st November, 2010 to 31st April, Methods: Patients with Cirrhosis of liver who were aged 13 years or above; of either gender with signs and symptoms of hepatic encephalopathy were enrolled in the study. Precipitating factors were determined by detailed history, examination and laboratory investigations. Patients presenting with fever were evaluated through detailed systemic examination, blood complete picture for leucocytosis, ascitic fluid routine examination in patients with ascites. Cirrhotic patients were classified into Group A, B and C according to Child Pugh classification. Results: Out of 148 patients, 129 (87.16%) were females. Hepatitis C was the cause of cirrhosis in 135 (90.54%). Child class C was found in 67(45.27%) of patients while 63(42.6%) had Child class B. On presentation 39.9 % of the patients were in Grade 1, while 31.9%, 16.9% and 12.2% were in grade 2, grade 3, and grade 4 respectively. The most common precipitating factors of hepatic encephalopathy, were constipation 51 (34.5%), infection 44(29.7%) and upper GI bleed 41(27.7%). The most common precipitant of Hepatic encephalopathy in Child class C was infection, while in class B and A, most common precipitating factor was GI bleed and constipation, respectively. Constipation had a important role in precipitation of Hepatic encephalopathy in all Child classes. Conclusion: The study concluded that the most common precipitating factors of hepatic encephalopathy are constipation, infection and gastrointestinal bleed. Infection is the leading precipitating factor of hepatic encephalopathy in Child Class C Keywords: Hepatic Encephalopathy, Child Pugh Classes, Liver Cirrhosis Introduction Liver Cirrhosis and its complications are a major health problem affecting millions of people world wide and in Pakistan. 3% of the world population has been infected with Hepatitis C virus. It is estimated that 10 million people of Pakistan are living with Hepatitis C infection. 1 Liver Cirrhosis is becoming an epidemic in Pakistan due to a very high prevalence of Hepatitis B and Hepatitis C in our community. 2 The increasing concern regarding Hepatitis C virus becoming Ann. Pak. Inst. Med. Sci

2 an epidemic and an important cause of Liver Cirrhosis in Pakistan. 3 In Europe, the prevalence of HCV antibodies has been reported to be ranging from 1% to 1.4% 4. HCV currently infects an estimated 2-3 million people in United States and 175 million people globally 4. With regard to incidence, most of the available data are from cross sectional studies of the selected high risk groups. Specifically, the incidence per 100 persons among drug users was reported to be 6.4 in Baltimore 5, 6.2 in Italy 6, and 11.7 in Switzerland 7. Data referring to general population or to countries with different anti HCV prevalence rates are scare, although studies show that the annual number of the newly acquired infections world wide has decreased from approximately in the mid 1980s to in 1995, and the major factors contributing to this decrease have been accurate screening of blood products and the active modification of risk factors. 8 Many cases of cryptogenic cirrhosis appear to have resulted from non alcoholic fatty liver disease (NAFLD). Fat builds up in the liver and eventually causes scar tissue. When cases of cryptogenic cirrhosis were reviewed, many patients had one or more of the classical risk factors for NAFLD i.e. Obesity, diabetes mellitus, coronary artery disease, hypertryglyceridemia and treatment with corticosteroid medications. Biopsy is needed for diagnosis. It is postulated that steatosis may regress in some patients as hepatic fibrosis progresses, making the histological diagnosis of NAFLD difficult. 9 Hepatic encephalopathy is a syndrome observed in patients with cirrhosis, characterized by personality changes, intellectual impairment and a depressed level of conciousness. 3,10 It occurs as an acute or chronic, progressive disorder that is associated with chronic liver disease. Both forms may result in irreversible coma and death. Approximately 80% (8 out of 10 patients) die if they go into coma. Recovery and risk of the recurrence vary from patient to patient. 11,12,13,14 Treatment of hepatic encephalopathy is mostly directed towards the cause or precipitating factors. Commonly reported precipitating factors are infections 44%, gastrointestinal bleeding 38% and constipation 38%. 2 When cirrhotic patients were grouped into child pugh classification, 62% patients were in class C and 28% were in class B. 2 Patients with hepatic encephalopathy are predisposed to develop problems with their quality of life. 15 Hepatic encephalopathy affects attention, working memory, response time and driving skills. In majority of the patients with hepatic encephalopathy, a clearly defined precipitating factor usually is identified, and the reversal and control of these factors is a key step in the management. Only few studies have been done in Pakistan to identify the precipitating cause of hepatic encephalopathy and none of these studies have mentioned precipitating factors in different severities of cirrhosis (child class). The study would help to identify the causative factors, leading to proper health education, early recognition and targeted treatment which would decrease the morbidity and mortality in such patients. Methodology The study was conducted in the three medical wards, emergency and intensive care unit of Fauji Foundation Hospital Rawalpindi. Duration of study was 06 months after the approval of synopsis i.e 1 st November, 2010 to 31 st April, 2011 The study population consisted of 148 patients who were enrolled in the study if they met the inclusion criteria. Data Collection Procedure: Patients with cirrhosis of liver those aged 13 years or above of either gender with signs and symptoms of hepatic encephalopathy were enrolled in the study. Informed consent was taken from the patients who were conscious and from the attendants of those patients who were unable to give the consent. Patients with cirrhosis were received by the same observer in emergency to avoid the observer bias. Acute fulminant hepatitis, Non Cirrhotic Portal Hypertension, Presence of other neurological disorders (stroke, meningitis, encephalitis), Patient with acute or chronic renal failure were excluded from the study. Hepatic encephalopathy was diagnosed based Stages of encephalopathy (see Annexure-A) whereas Child Pug Class according to Child Pugh Grading System was explained (see Annexure-B). Precipitating factors like Constipation defined by Less than 2 stools in 24 hours 2. Gastrointestinal bleed: history of haematemesis or maelena and Infection defined as raised total leukocyte count of more than /l 2, 3.:Polymorphoneuclear cells (PMNs) >250/mcL on ascitic fluid examination 2,3 Precipitating factors were determined by detailed history, examination and laboratory investigations. History included questions regarding gastrointestinal bleed, Ann. Pak. Inst. Med. Sci

3 constipation, fever, diarrhea and intake of drugs (benzodiazepines, opiates, hypnotics, diuretics). Examination was performed for severity of ascites and grades of hepatic encephalopathy and to identify the source of infection. Investigations included hepatitis serology (for Hepatitis B and C by Elisa), serum bilirubin, serum albumin, prothombin time, serum electrolytes, serum urea, creatinine and blood complete picture. All these investigations were performed in the pathology department of Fauji Foundation hospital. Patients presenting with fever were evaluated through detailed systemic examination, blood complete picture for leucocytosis, ascitic fluid routine examination in patients with ascites. Cirrhotic patients were classified into Group A, B and C according to Child Pugh classification. The data was entered in the worksheet specially prepared for the study using the Statistical Package for Social Sciences version Mean +/- SD calculated for quantitative variables such as age, serum bilirubin, prothrombin time, and serum albumin. Frequency and percentages presented for qualitative variables like gender, grades of hepatic encephalopathy and different precipitating factors. A separate table was made showing descriptive statistics of above mentioned variables in each child class. Results Mean age was 59.97± Only 12.84% of our study population was male. Majority of study population was female i.e % of patients. with % was HCV positive. Only 4.05% were found to be HBV positive. In 5.41% of total study population we neither found HCV nor HBV. We assessed the severity of cirrhosis on the basis of Child Pugh score in our study population % of total patients were found to be in Child Class C, 42.57% in Child Class B and only % in Child Class A. Patients with Hepatic Encephalopathy were assessed and graded by clinical assessment. Most of the patients were in Hepatic Encephalopathy Grade 1, i.e 39.86%. Second most common was grade 2 i.e % % patients were in grade 3, and only 12.16% patients of total study population in Grade 4 as shown in Table No. 01. Serum bilirubin was found significantly high in patients with child class C i.e.55±12µmol/l as compared with child class A where serum bilirubin is almost normal i.e.14±4µmol/l while in child class B it was moderately raised i.e.24±6µmol/l. Table No 1 Results of study Characteristics Demographic Characteristics Age mean Gender: (years) Males Females Hepatitis serology HCV positive 90.54s% HBV positive 4.05% HCV and HBV negative 5.54% Child class Patients evaluated n= ± (12.84%) 129 (87.16%) Child class A 18(12.16%) Child class B 63(42.57%) Child class C 67(45.27%) Grades of hepatic encephalopathy Grade 1 59(39.86%) Grade 2 46(31.08%) Grade 3 25(16.89%) Grade 4 18(12.16%) Precipitating factors of hepatic encephalopathy in total study population Infection 44 (29.7%) GI bleed 41 (27.7%) Constipation 51 (34.5 %) Diarrhea 4 (2.7%) Drugs 1 (0.7%) No cause found 4 (2.7%) Others 3 (2.0%) Total 148 (100.0%) Serum albumin decreased with severity of disease.i.e. 38±4mg/dl, 29±5mg/dl and 23±4mg/dl in Child Class A, B and C respectively. Likewise another synthetic liver function, prothrombin time was normal in Child Class A i.e. 98% of patients in Child class A had normal PT. In Child Class B it was prolonged (4-6sec) in 50% of the patients. While in Child Class C, Prothrombin time was significantly prolonged i.e.51% of the patients in child class C had prolonged PT of more than 6 seconds as shown in Table. No. 02 In our study, the leading precipitating factor for hepatic encephalopathy was constipation i.e. 34.5% followed by Ann. Pak. Inst. Med. Sci

4 Infection and Upper GI bleed, 29.73%and 27.70% respectively. Less common causes were diarrhea in only 2.7 %, drugs in 0.7 % of total study population. In only 4 % of patients no precipitating cause was found. The most common precipitating factor of Hepatic encephalopathy in Child class A was Constipation. In Child Class B, Gastrointestinal bleed was the leading precipitating factor. The most common precipitating factor in Child Class C was infection. Out of 67(45.27%) patients in Child class C, in 27(40.29%) patients, precipitating factor was infection followed by constipation i.e. 21(31%). In Child Class B, 0ut of 63(42.56% patients of total patients) GI bleed was responsible precipitating factor in 23(36.50%) patients followed by constipation and infection in 20(31%) & 15(23%) patients respectively. Constipation is Commonest precipitating factor of hepatic encephalopathy in each Child Class as shown in Table. No. 03 Table No 2. Laboratory Investigations Lab Investigations Serum Bilirubin (μmol/l ) (mean ±SD) Serum Albumin (g/l) (mean ±SD) Prothrombin Time 0-4sec 4-6sec >6 sec Child Pugh Score A B C 14±4 24±6 55±12 38±4 29±5 23±4 98% 2% 0% 30% 50% 20% 15% 34% 51% Table No 3. Identified precipitating factor based on Child Pugh class Identified precipitating factor Child Class A Severity of Cirrhosis (Child Pugh score) Child Class B Child Class C Total Infection GI bleed Constipation Diarrhea Drugs no cause found Others Total Discussion Hepatic encephalopathy is the most common complication of liver Cirrhosis and patients with Hepatic Encephalopathy are predisposed to develop problems with their quality of life 4, Identification of the precipitating factor is important because it would help to identify the causative factor and in targeted treatment 8. In majority of the patients a clearly defined precipitating factor is identified and the reversal or control of that factor is the important step of management of patients with hepatic encephalopathy. In my study, I analyzed the possible important precipitating factors that can precipitate hepatic encephalopathy and the most common factors in different severities of cirrhosis (Child Class) Out of 148 patients 128(87.16%) patients were female and 20(12.84%) were female. Mumtaz 16 shows that 62% of the study population were males In my study, it seems that it is almost exclusively a disease of females but the reason is that in our hospital we mainly treat the families of retired army personals. Majority of the patients were in the age group of years. Mean age was 59 years, while study done by Alam 3 in N.W.F.P most of the patients were in age group years. There was a wide range of age among the study population. Out of 148 patients 90.54% were HCV positive and only 4.05 % were HBV positive. 5.41% of total study population was both B&C negative. Studies done in Pakistan suggest that HCV is the leading cause of cirrhosis in Pakistan. 1, 2, 3 Mumtaz 16 also found in his study that HCV was the cause of cirrhosis in 70% of the patients. Hepatitis C is increasing dangerously as the cause of cirrhosis in our country as compared to the western world where alcoholism is the main cause of cirrhosis and where there is definite male preponderance to the extent of 77:33. Faloon 19 found that, it is the 4 th commonest cause of death in USA. In my study I did not find any patient with both HCV &HBV positive. In Child Class C, serum albumin was low and it indicates the severity of cirrhosis, as serum bilirubin is the synthetic function of liver. Similarly prothrombin time was prolonged significantly in Child Class C due to the same reason. Serum bilirubin increased with the severity of cirrhosis. These are all parameters of Child Classification and indicate advanced liver disease. Maqsood 2 found in his study that 62% of the total selected patients were in Child Cass C, 28% in Class B and 4 % in child class A. My study shows that 45.27% of the patients were in class C, while 42.57% of patients were in class B and only 12.2% in Child Class A. The percentage Ann. Pak. Inst. Med. Sci

5 was almost the same in both class B&C. I have included not only admitted patients but also patients seen in emergency as well. Kumar 17 conducted a study in Hyderabad. Results show that 80 % of total patients were in Grade IV, 9% in Grade III, 6% in Grade II, and 5% in Grade I. In my study, only 12.16% were in grade IV, 31.08% were in Grade II. Almost 40% of total patients were in grade I and 16.89% were in grade III. Most of the population in my study was in grade I and II and the outcome was excellent in grade I&II as compared to grade III&IV. Similarly lesser the grade of hepatic encephalopathy, shorter was the stay in hospital. In local studies, the most common precipitating factors of Hepatic Encephalopathy were infection, constipation, and upper GI bleed. Tariq 18 published almost the similar results where constipation and the infection were the leading precipitating factors i.e. 30% each, followed by GI bleed (29%). Maqsood 2 shows that infection 44%, gastrointestinal bleed 38% and constipation 38% stood out as the most common precipitating factors. In my study constipation stood as the leading precipitating factor in total study population i.e. 34.5%. Other common precipitating factors were Infection and gastrointestinal bleed, 29.7% and 27.7% respectively. These results are close to the earlier published statistics as stated above. But I have found in my study that the most common precipitating factor is constipation instead of infection in total study population but infection is leading precipitating factor in Child Class C. International data suggests that constipation is not the commonest precipitating factor. Faloon 19, Souheil 20 and Conn 21 reported constipation in 6%, 3% and 3% of their cases respectively. But my study and local literatures reveal that constipation is a key factor in precipitation of hepatic encephalopathy. Infection is the second commonest precipitating factor of Hepatic encephalopathy in total study population, leading precipitant in Child class C and in other local studies 16. International data shows Souheil 20 found infections responsible in only 3% of cases and Conn 21 found infection responsible in only 4% of cases. Increased total leukocyte count (TLC) suggested infection. Commonly found infections were urinary tract infection, respiratory tract infection and spontaneous bacterial peritonitis. High frequency of infection in our country is probably because of unhygienic conditions and poor nutritional status. Gastrointestinal bleed is another common precipitating factor found in my study. i.e. acute variceal bleed presented as Hemetemesis, maelena or both. Results are almost similar to the local studies. Less common precipitating factors identified in my study were diarrhea only in 4(4.7%) and drugs (benzodiazepines) only in 1(0.7%) in whole study population. very small fraction of patients (1.9%) had electrolyte imbalance, vomiting, hyperglycemia. No cause was found in only 4 (1.9%) of patients as compared to a study by Mumtaz 16 where in 12% of patients no precipitant was noted. None of the studies have mentioned the precipitating factor in different severities of cirrhosis (child class). In my study I have analyzed different precipitating factors in different child class so that we can predict precipitating factor in a better way and similarly to find out that which factor is more common in which class. According to my statistics infection is the most common precipitating factor in Child class C. Out of 67(45.27%) patients in Child class C, in 27(40.29%) patients, precipitating factor was infection followed by constipation i.e. 21(31%). It is probably because of nutritional status, malnourishment, and unhygienic conditions. GI bleed is the leading precipitant in Child Class B. 0ut of 63(42.56% patients of total patients) GI bleed was responsible precipitating factor in 23(36.50%) patients followed by constipation and infection in 20(31%) & 15(23%) patients respectively. While in child Class A constipation was the leading factor. One very important finding in this study is that constipation has significant role in the precipitation of hepatic encephalopathy in all Child Pugh Classes and hence affecting the quality of life and cost effectiveness in medical wards. That is probably because of dietary patterns, social taboos, poor compliance with lactulose, poor health education and inadequate understanding of the disease among patients and their attendants. Conclusion Most of the patients with Hepatic Encephalopathy had an identifiable precipitating factor. Constipation, Infection and upper GI bleed were the most frequent precipitating factors. Infection is most significantly frequent precipitating factor in Child Class C. Constipation is the commonest precipitating factor in all child class. Prevention of constipation by laxatives, proper dietary advice, adherence to the treatment Ann. Pak. Inst. Med. Sci

6 and proper health education needs to be given importance. Likewise prompt control of infection, and use of prophylactic antibiotics for infection, prophylactic use of ß blockade, variceal banding for GI bleed and more importantly proper counseling are the measures that can improve the quality of life of the patients and can ultimately decrease the burden of admissions in medical wards. References 1. Raja NS, Janjua KA. Epidemiology of Hepatitis C virus in Pakistan. J Microbial Immunol Infect 2008; 41: Maqsood S, Saleem A, Iqbal A, Aslam JB. Precipitating factors of Hepatic Encephalopathy: Experienced at Pakistan Institute of Medical Sciences Islamabad. J Ayub Med Coll Abbotabad 2006; 18: Alam I, Razaullah, Haider I, Hamayun M, Taqweem A, Nisar M. Spectrum of Precipitating Factors of Hepatic Encephalopathy in Liver Cirrhosis. Pak J Med Res 2005; 44: Sarbah SA, Younossi ZM. Hepatitis C, an update on the silent epidemic. J Clin Gastroenterol 2000; 30: Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for Hepatitis C among injection drug users in Baltimore, Maryland. J Clin Microbial 1997; 35: Galeazzi B, Tufano A, Barbierato E, Bortolotti F. Hepatitis C infection in Italian intravenous drug users: Epidemiological and clinical aspects. Liver 1995; 15: Chamot E, Sassurep DE, Hirschel B, Déglon JJ, Perrin LH Incidence of Hepatitis C, Hepatitis B and HIV infections among drug users in methadone- maintenance programme. AIDS 1992 ;6: Alter MJ, Kruszon-Moran D, Nainan OV, McQuillan GM, Gao F, Moyer LA, et al. The prevalence of Hepatitis C virus infection in the United States, 1988 through N Engl J Med 1999; 341: American gastroenterological association medical position statement: nonalcoholic fatty liver disease. Gastroenterology 2002;123: Riggio O, Efrati C, Catalano C. High prevalence of Spontaneous portal systemic shunts in persistent Hepatic Encephalopathy: A case control study. Hepatology 2005; 42: Schuppan D, Afdhal NH. Liver Cirrhosis. Lancet. 2008; 371: Groszmann, RJ and Abraldes, JG. Portal hypertension. From bedside to bench. J Clin Gastroenterol. 2005; 39: S125 S Qayyum, A, Goh, JS, Kakar, S et al. Accuracy of liver fat quantification at MR imaging: comparison of out-of-phase gradient-echo and fat-saturated fast spin-echo techniques initial experience.radiology. 2005; 237: Munoz SJ. Hepatic encephalopathy. Med Clin North Am 2008; Stephen M, Riordan, William R. Gut flora and hepatic encephalopathy in patients with Cirrhosis. NEJM 2010; 362: Mumtaz K, Ahmed US, Abid S, Baig N, Hamid S, et al. Precipitating Factors and Outcome of Hepatic Encephalopathy in Liver Cirrhosis. J Coll Physcians and Surg Pak 2010; 20: Kumar D, Derajani BR, Shah SZ Kumar D. Precipitating Factors of Hepatic Encephalopathy at tertiary care hospital Jomshoro Hyderabad J Pak Med Association 2009; 59: Tariq M, Iqbal S, Khan NU, Basri R. Precipitating Factors of Hepatic Encephalopathy Rawal Med J 2009 ;34: Faloon WW, Evan GL. Precipitating Factors in Genesis of Hepatic Coma. N Y State J Med 1970; 1; 70: Abou-Assi S, Vlahcevic Z. Hepatic Encephalopathy. Metabolic consequence of cirrhosis often is reversible. Postgrad Med J 2001; 109: Conn Ho, Leiberlhal MM. Hepatic Coma Syndrome and Lactulose.1st Edition, Baltimore: Williams & Wilkins; 1980:106 Ann. Pak. Inst. Med. Sci

Severity and Mortality Prediction in Chronic Liver Disease using Child PUGH and MELD scales

Severity and Mortality Prediction in Chronic Liver Disease using Child PUGH and MELD scales International Journal of Advanced Biotechnology and Research (IJABR) ISSN 0976-2612, Online ISSN 2278 599X, Vol-10, Issue-1, 2019, pp519-524 http://www.bipublication.com Research Article Severity and Mortality

More information

Original Article PLATELET COUNT TO SPLEEN DIAMETER RATIO AS A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS OF LIVER CIRRHOSIS DUE TO HEPATITIS C VIRUS

Original Article PLATELET COUNT TO SPLEEN DIAMETER RATIO AS A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS OF LIVER CIRRHOSIS DUE TO HEPATITIS C VIRUS Original Article AS A PREDICTOR OF ESOPHAGEAL VARICES IN PATIENTS OF LIVER CIRRHOSIS DUE TO HEPATITIS C VIRUS Khalid Amin 1, Dilshad Muhammad 2, Amin Anjum 3, Kashif Jamil 4, Ali Hassan 5 1 Associate Professor

More information

Corresponding Author: Dr. Ali Saqib, Department of Medicine, Madina Teaching Hospital, Faisalabad.

Corresponding Author: Dr. Ali Saqib, Department of Medicine, Madina Teaching Hospital, Faisalabad. Original Article FREQUENCY OF SPONTANEOUS BACTERIAL PERITONITIS (SBP) IN CIRRHOTIC PATIENTS WITH ASCITES DUE TO HEPATITIS B AND C Ali Saqib 1, Rizwan Rasul Khan 2, Zahid Masood 3, Irshad ul Haque 4 1 Assistant

More information

Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology

Ascites Management. Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Ascites Management Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH have no relevant

More information

Original Article. Authors

Original Article. Authors Original Article APMC-336 Analysis of Identifiable Risk Factors Precipitating Acute Encephalopathy in Chronic Liver Disease, At PNS Shifa Karachi Javed Iqbal, Muhammad Akhtar Parvez, Muhammad Mehboob Alam

More information

Management of Cirrhosis Related Complications

Management of Cirrhosis Related Complications Management of Cirrhosis Related Complications Ke-Qin Hu, MD, FAASLD Professor of Clinical Medicine Director of Hepatology University of California, Irvine Disclosure I have no disclosure related to this

More information

JMSCR Vol 05 Issue 11 Page November 2017

JMSCR Vol 05 Issue 11 Page November 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i11.33 Prevalence of Hyponatremia among patients

More information

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University

Management of Cirrhotic Complications Uncontrolled Ascites. Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Management of Cirrhotic Complications Uncontrolled Ascites Siwaporn Chainuvati, MD Siriraj Hospital Mahidol University Topic Definition, pathogenesis Current therapeutic options Experimental treatments

More information

CHAPTER 1. Alcoholic Liver Disease

CHAPTER 1. Alcoholic Liver Disease CHAPTER 1 Alcoholic Liver Disease Major Lesions of Alcoholic Liver Disease Alcoholic fatty liver - >90% of binge and chronic drinkers Alcoholic hepatitis precursor of cirrhosis Alcoholic cirrhosis end

More information

King Abdul-Aziz University Hospital (KAUH) is a tertiary

King Abdul-Aziz University Hospital (KAUH) is a tertiary Modelling Factors Causing Mortality in Oesophageal Varices Patients in King Abdul Aziz University Hospital Sami Bahlas Abstract Objectives: The objective of this study is to reach a model defining factors

More information

Associate Professor,Department Of Radiology, Malda Medical College, Malda. Corresponding author: *Dr.Gauranga Biswas

Associate Professor,Department Of Radiology, Malda Medical College, Malda. Corresponding author: *Dr.Gauranga Biswas IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 16, Issue 7 Ver. II (July. 2017), PP 50-54 www.iosrjournals.org A Comparative Study to Determine the

More information

J of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 4/ Issue 66/ Aug 17, 2015 Page 11478

J of Evolution of Med and Dent Sci/ eissn , pissn / Vol. 4/ Issue 66/ Aug 17, 2015 Page 11478 A STUDY OF THE CLINICAL PROFILE OF CIRRHOSIS OF LIVER AND ANALYSIS OF PRECIPITATING FACTORS IN HEPATIC ENCEPHALOPATHY Sai Lakshmi Bharathi 1, Vengadakrishnan K 2, Rajkumar M 3 HOW TO CITE THIS ARTICLE:

More information

Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar

Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Original Research Article Prevalence of non-alcoholic fatty liver disease in type 2 diabetes mellitus patients in a tertiary care hospital of Bihar Naresh Kumar 1, Jyoti Kumar Dinkar 2*, Chandrakishore

More information

GI bleeding in chronic liver disease

GI bleeding in chronic liver disease GI bleeding in chronic liver disease Stuart McPherson Consultant Hepatologist Liver Unit, Freeman Hospital, Newcastle upon Tyne and Institute of Cellular Medicine, Newcastle University. Case 54 year old

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function tests / tests of

More information

Role of Branched Chain Amino Acids in Hepatic Encephalopathy

Role of Branched Chain Amino Acids in Hepatic Encephalopathy ORIGINAL ARTICLE (APMC 378) DOI: 10.29054/APMC/17.378 Role of Branched Chain Amino Acids in Hepatic Encephalopathy Umair Ahmed, Aamir Shaukat, Hooria Aamir, Awais Ahmed ABSTRACT Introduction: Hepatic encephalopathy

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant. Susan Kang, RN, MSN, ANP-BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP-BC Introduction (https://www.srtr.org) What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC

End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC End Stage Liver Disease & Disease Specific Indications for Liver Transplant Susan Kang, RN, MSN, ANP BC Introduction (https://www.srtr.org) 1 What does the liver do? STORAGE METABOLIC DETOXIFICATION SYNTHETIC

More information

Healthy Liver Cirrhosis

Healthy Liver Cirrhosis Gioacchino Angarano Clinica delle Malattie Infettive Università degli Studi di Foggia Healthy Liver Cirrhosis Storia naturale dell epatite HCVcorrelata in assenza di terapia Paestum 13-15 Maggio 24 The

More information

Learning Objectives. After attending this presentation, participants will be able to:

Learning Objectives. After attending this presentation, participants will be able to: Learning Objectives After attending this presentation, participants will be able to: Describe HCV in 2015 Describe how to diagnose advanced liver disease and cirrhosis Identify the clinical presentation

More information

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018)

Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) PREFERRED AGENTS: (See drug specific NOTES for exceptions.) Protocol for daclatasvir (Daklinza ) Approved October 2015 (updated February 2018) https://providers.amerigroup.com For genotype 1, Mavyret and

More information

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea

DISCLOSURES. This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea DISCLOSURES This activity is jointly provided by Northwest Portland Area Indian Health Board and Cardea Cardea Services is approved as a provider of continuing nursing education by Montana Nurses Association,

More information

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association

Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association CIRRHOSIS AND PORTAL HYPERTENSION Cirrhosis and Portal Hypertension Gastroenterology Teaching Project American Gastroenterological Association WHAT IS CIRRHOSIS? What is Cirrhosis? DEFINITION OF CIRRHOSIS

More information

Complications of Cirrhosis

Complications of Cirrhosis Complications of Cirrhosis Causes of Cirrhosis Alcohol Chronic Viral Hepatitis (B/C) Haemochromatosis Autoimmune Hepatitis NAFLD/NASH Primary Biliary Cirrhosis Primary Sclerosing Cholangitis 1-AT deficiency

More information

CONTROLLED DOCUMENT. Cirrhosis Care Bundle CATEGORY: Clinical Guidelines. CLASSIFICATION: Clinical. Controlled Document CG201 Number:

CONTROLLED DOCUMENT. Cirrhosis Care Bundle CATEGORY: Clinical Guidelines. CLASSIFICATION: Clinical. Controlled Document CG201 Number: Cirrhosis Care Bundle CONTROLLED DOCUMENT CATEGORY: Clinical Guidelines CLASSIFICATION: Clinical Controlled Document CG201 Number: Version Number: 1 Controlled Document Clinical Guidelines Group Sponsor:

More information

Liver failure &portal hypertension

Liver failure &portal hypertension Liver failure &portal hypertension Objectives: by the end of this lecture each student should be able to : Diagnose liver failure (acute or chronic) List the causes of acute liver failure Diagnose and

More information

Hepatocellular Carcinoma (HCC)

Hepatocellular Carcinoma (HCC) Title Slide Hepatocellular Carcinoma (HCC) Professor Muhammad Umar MBBS, MCPS, FCPS (PAK), FACG (USA), FRCP (L), FRCP (G), ASGE-M(USA), AGAF (USA) Chair & Professor of Medicine Rawalpindi Medical College

More information

Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL

Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Management of Acute Decompensation of Cirrhosis JOHN O GRADY KING S COLLEGE HOSPITAL Terminology Acute decompensation of cirrhosis - stable patient with sudden deterioration Acute-on-chronic liver failure

More information

Int. J. Pharm. Sci. Rev. Res., 46(1), September - October 2017; Article No. 07, Pages: 37-41

Int. J. Pharm. Sci. Rev. Res., 46(1), September - October 2017; Article No. 07, Pages: 37-41 Research Article Assessment of Clinical Profile and Prescription Pattern of Drugs in Alcoholic Liver Disease and Hepatitis in a Tertiary Care Hospital Christeena James*, Dr.ShirishInamdar, Dr.Bharathi

More information

Hepatology for the Nonhepatologist

Hepatology for the Nonhepatologist Hepatology for the Nonhepatologist Kenneth E. Sherman, MD, PhD Gould Professor of Medicine Director, Division of Digestive Diseases University of Cincinnati College of Medicine Cincinnati, Ohio Learning

More information

FREQUENCY OF HEPATITIS B AND C IN HEALTHY SUBJECTS IN PARACHINAR

FREQUENCY OF HEPATITIS B AND C IN HEALTHY SUBJECTS IN PARACHINAR ORIGINAL ARTICLE FREQUENCY OF HEPATITIS B AND C IN HEALTHY SUBJECTS IN PARACHINAR Munir Hussain Bangash, Tanweer Hussain Bangash, Jabar Ali Department of Medicine and Department of Dentistry Agency Head

More information

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust

The Yellow Patient. Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust The Yellow Patient Dr Chiradeep Raychaudhuri, Consultant Hepatologist, Hull University Teaching Hospitals NHS Trust there s a yellow patient in bed 40. It s one of yours. Liver Cirrhosis Why.When.What.etc.

More information

Correlation of Child Pugh Class of Cirrhosis and Lipid Profile

Correlation of Child Pugh Class of Cirrhosis and Lipid Profile Proceeding S.Z.P.G.M.I. Vol: 30(1): pp. 19-23, 2016. Correlation of Child Pugh Class of Cirrhosis and Lipid Profile Muhammad Israr Ul Haq, Adnan Salim, Kashif Malik, Akif Dilshad, Johar Amin, Arshad Kamal

More information

Liver Disease. By: Michael Martins

Liver Disease. By: Michael Martins Liver Disease By: Michael Martins Recently I have been getting a flurry of patients that have some serious liver complications. This week s literature review will be the dental management of the patients

More information

Life After SVR for Cirrhotic HCV

Life After SVR for Cirrhotic HCV Life After SVR for Cirrhotic HCV KIM NEWNHAM MN, NP CIRRHOSIS CARE CLINIC UNIVERSITY OF ALBERTA Objectives To review the benefits of HCV clearance in cirrhotic patients To review some of the emerging data

More information

B C Outlines. Child-Pugh scores

B C Outlines. Child-Pugh scores B C 2016-12-09 Outlines Child-Pugh scores CT MRI Fibroscan / ARFI Histologic Scoring Systems for Fibrosis Fibrosis METAVIR Ishak None 0 0 Portal fibrosis (some) 1 1 Portal fibrosis (most) 1 2 Bridging

More information

Alcoholic Hepatitis: Routine Screening for Early Recognition and Management. Juan Guerrero, MD

Alcoholic Hepatitis: Routine Screening for Early Recognition and Management. Juan Guerrero, MD Alcoholic Hepatitis: Routine Screening for Early Recognition and Management Juan Guerrero, MD Global Problem 1% of GNP of medium/high income countries Additional societal costs Disproportionately affects

More information

LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use.

LIVER CIRRHOSIS. The liver extracts nutrients from the blood and processes them for later use. LIVER CIRRHOSIS William Sanchez, M.D. & Jayant A. Talwalkar, M.D., M.P.H. Advanced Liver Disease Study Group Miles and Shirley Fiterman Center for Digestive Diseases Mayo College of Medicine Rochester,

More information

Prevalence of Impaired Glucose Tolerance and its Utility to Predict Prognosis of Patients with Liver Cirrhosis

Prevalence of Impaired Glucose Tolerance and its Utility to Predict Prognosis of Patients with Liver Cirrhosis American Research Journal of Medicine and Surgery ISSN (Online) : 2379-8955, 6 pages Research Article Prevalence of Impaired Glucose Tolerance and its Utility to Predict Prognosis of Patients with Liver

More information

Patterns of abnormal LFTs and their differential diagnosis

Patterns of abnormal LFTs and their differential diagnosis Patterns of abnormal LFTs and their differential diagnosis Professor Matthew Cramp South West Liver Unit and Peninsula Schools of Medicine and Dentistry, Plymouth Outline liver function / liver function

More information

Module 1 Introduction of hepatitis

Module 1 Introduction of hepatitis Module 1 Introduction of hepatitis 1 Training Objectives At the end of the module, trainees will be able to ; Demonstrate improved knowledge of the global epidemiology of the viral hepatitis Understand

More information

Causes of Liver Disease in US

Causes of Liver Disease in US Learning Objectives Updates in Outpatient Cirrhosis Management Jennifer Guy, MD MAS Director, Liver Cancer Program California Pacific Medical Center guyj@sutterhealth.org Review cirrhosis epidemiology,

More information

Improving Access to Quality Medical Care Webinar Series

Improving Access to Quality Medical Care Webinar Series Improving Access to Quality Medical Care Webinar Series Presented by The Arizona Telemedicine Program and the Southwest Telehealth Resource Center 2015 UA Board of Regents Welcome AZ, UT, CO, NM & NV FLEX

More information

Dietary Practices and Beliefs of Patients with Chronic Liver Disease

Dietary Practices and Beliefs of Patients with Chronic Liver Disease Dietary Practices and Beliefs of Patients with Chronic Liver Disease Pages with reference to book, From 216 To 220 Salma H. Badruddin,S. M. Wasim Jafri,Ashfaq Ahmed,Shahab Abid ( Department of Medicine

More information

Chronic Hepatic Disease

Chronic Hepatic Disease Chronic Hepatic Disease 10 th Leading Cause of Death Liver Functions Energy Metabolism Protein Synthesis Solubilization, Transport, and Storage Protects and Clears drugs, damaged cells Causes of Liver

More information

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV

Steps in Assessing Fibrosis 4/30/2015. Overview of Liver Disease Associated With HCV Overview of Liver Disease Associated With HCV Marion G. Peters, MD John V. Carbone, Endowed Chair Professor of Medicine Chief of Hepatology Research University of California San Francisco San Francisco,

More information

Liver disease in 2017: challenges and opportunities

Liver disease in 2017: challenges and opportunities Liver disease in 2017: challenges and opportunities Dr Matthew Cowan Consultant Gastroenterologist and Hepatologist Surrey and Sussex Healthcare NHS Trust Faculty of Physician Associates 2 nd National

More information

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC.

DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC. DIFFERENTIAL BENEFITS OF DAAs IN DIFFERENT PATIENT POPULATIONS. IN PATIENTS ON A WAITING LIST FOR TRANSPLANTATION. THE CLINIC. Robert J. de Knegt, Erasmus MC, Rotterdam r.deknegt@erasmusmc.nl Disclosures

More information

Assessment of Liver Function: Implications for HCC Treatment

Assessment of Liver Function: Implications for HCC Treatment Assessment of Liver Function: Implications for HCC Treatment A/P Dan Yock Young MBBS, PhD, MRCP, MMed. FAMS Chair, University Medicine Cluster. NUHS Head, Department of Medicine, National University of

More information

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL

DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL DISEASE LEVEL MEDICAL EVIDENCE PROTOCOL 1. This Protocol sets out the medical evidence that must be delivered to the Administrator for proof of Disease Level. It is subject to such further and other Protocols

More information

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry

WEEK. MPharm Programme. Liver Biochemistry. Slide 1 of 49 MPHM14 Liver Biochemistry MPharm Programme Liver Biochemistry Slide 1 of 49 MPHM Liver Biochemistry Learning Outcomes Assess and evaluate the signs and symptoms of illness Assess and critically appraise a patients medication regimen,

More information

HEPATITIS C: A LEADING CAUSE OF CIRRHOSIS IN PATIENTS PRESENTING AT DHQ TEACHING HOSPITAL D.I.KHAN

HEPATITIS C: A LEADING CAUSE OF CIRRHOSIS IN PATIENTS PRESENTING AT DHQ TEACHING HOSPITAL D.I.KHAN E:/Biomedica Vol.23 Jul. Dec. 2007/Bio-7 (A) HEPATITIS C: A LEADING CAUSE OF CIRRHOSIS IN PATIENTS PRESENTING AT DHQ TEACHING HOSPITAL D.I.KHAN 1IHSANULLAH MAHSUD, 2 REHMAN-UD-DIN, 3 HABIBULLAH KHAN, 4

More information

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors

Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Hepatitis C: Management of Previous Non-responders with First Line Protease Inhibitors Fred Poordad, MD The Texas Liver Institute Clinical Professor of Medicine University of Texas Health Science Center

More information

Management of the Cirrhotic Patient in the ICU

Management of the Cirrhotic Patient in the ICU Management of the Cirrhotic Patient in the ICU Peter E. Morris, MD Professor & Chief, Pulmonary, Critical Care and Sleep Medicine University of Kentucky Conflict of Interest Funding US National Institutes

More information

JMSCR Vol 05 Issue 04 Page April 2017

JMSCR Vol 05 Issue 04 Page April 2017 www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 83.27 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i4.202 A Study on Clinical and Laboratory Features

More information

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014

Faculty Disclosure. Objectives. Cirrhosis Management for the Family Physician 18/11/2014 Cirrhosis Management for the Family Physician Mang Ma, MD, FRCP Professor University of Alberta Faculty: Mang Ma Faculty Disclosure Relationships with commercial interests: Advisory Board: Merck, Gilead

More information

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS?

IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? IS THERE A DIFFERENCE IN LIVER CANCER RATES IN PATIENTS WHO RECEIVE TREATMENT FOR HEPATITIS? Dr. Sammy Saab David Geffen School of Medicine, Los Angeles, USA April 2018 DISCLAIMER Please note: The views

More information

Hepatic Encephalopathy

Hepatic Encephalopathy Hepatic Encephalopathy John Barber UMassMedical Student, Class of 2019 www.12daysinmarch.com Outline Overview Normal Physiology Pathology Symptoms Diagnosis Treatment Overview Ammonia (NH 3 ) is a byproduct

More information

Alpha-1 Antitrypsin Deficiency: Liver Disease

Alpha-1 Antitrypsin Deficiency: Liver Disease Alpha-1 Antitrypsin Deficiency: Liver Disease Who is at risk to develop Alpha-1 liver disease? Alpha-1 liver disease may affect children and adults who have abnormal Alpha-1 antitrypsin genes. Keys to

More information

INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS

INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS INCIDENCE OF BACTERIAL INFECTIONS IN CIRRHOSIS Yoshida H et al (1993)* Deschenes M et al (1999)** Strauss E et al (1993) Borzio M et al (2002) PATIENTS 1140 140 170 405 INFECTIONS 15.4% 20% 47% 34% * Many

More information

A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy

A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of Overt Hepatic Encephalopathy 1458 ORIGINAL CONTRIBUTIONS nature publishing group see related editorial on page x A Randomized, Double-Blind, Controlled Trial Comparing Rifaximin Plus Lactulose With Lactulose Alone in Treatment of

More information

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA

CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Cagliari, 16 settembre 2017 CIRROSI E IPERTENSIONE PORTALE NELLA DONNA Vincenza Calvaruso, MD, PhD Ricercatore di Gastroenterologia Gastroenterologia & Epatologia, Di.Bi.M.I.S. Università degli Studi di

More information

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph

Esophageal Varices Beta-Blockers or Band Ligation. Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation Cesar Yaghi MD Hotel-Dieu de France University Hospital Universite Saint Joseph Esophageal Varices Beta-Blockers or Band Ligation? Risk of esophageal variceal

More information

Hepatitis C Update on New Treatments

Hepatitis C Update on New Treatments Hepatitis C Update on New Treatments Kevork M. Peltekian, MD, FRCPC 44th Annual Dalhousie Spring Refresher Course - Therapeutics April 5 - April 7, 2018 Halifax Convention Centre Disclosures Conflicts

More information

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting?

Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? Rajani Sharma, PGY1 Geriatrics CRC Project, 12/19/13 Are we adequately screening at-risk patients for hepatocellular carcinoma in the outpatient setting? A. Study Purpose and Rationale Hepatocellular carcinoma

More information

Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College

Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College Ari Bunim, M.D. Director of Hepatology New York Hospital Queens Assistant Professor of Clinical Medicine Weill Cornell Medical College New York State Law Goes into Effect January 1, 2014 Hepatitis C Virus

More information

NON-B, NON-C HEPATITIS AS A CAUSE OF ADVANCED CHRONIC LIVER DISEASE REQUIRING MEDICAL ADMISSION AT A RURAL CENTRE IN PAKISTAN

NON-B, NON-C HEPATITIS AS A CAUSE OF ADVANCED CHRONIC LIVER DISEASE REQUIRING MEDICAL ADMISSION AT A RURAL CENTRE IN PAKISTAN Original Article NON-B, NON-C HEPATITIS AS A CAUSE OF ADVANCED CHRONIC LIVER DISEASE REQUIRING MEDICAL ADMISSION AT A RURAL CENTRE IN PAKISTAN Muhammad Ali 1, Syed Zafar Abbas 2, Farhat Sultana 3, Waseem

More information

An Assessment of Hepatitis C Virus Screening and Treatment Practices of Providers Serving Individuals with Limited Resources

An Assessment of Hepatitis C Virus Screening and Treatment Practices of Providers Serving Individuals with Limited Resources An Assessment of Hepatitis C Virus Screening and Treatment Practices of Providers Serving Individuals with Limited Resources Andrea Jones Johns Hopkins School of Public Health Robin Decker Hepatitis C

More information

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis

ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis ACG & AASLD Joint Clinical Guideline: Prevention and Management of Gastroesophageal Varices and Variceal Hemorrhage in Cirrhosis Guadalupe Garcia-Tsao, M.D., 1 Arun J. Sanyal, M.D., 2 Norman D. Grace,

More information

Management of Hepatic Encephalopathy

Management of Hepatic Encephalopathy Management of Hepatic Encephalopathy Atif Zaman, MD MPH Oregon Health & Science University Professor of Medicine Division of Gastroenterology and Hepatology Disclosure 1. The speaker Atif Zaman, MD MPH

More information

Intradialytic Parenteral Nutrition in Hemodialysis Patients. Hamdy Amin, Pharm.D., MBA, BCNSP Riyadh, Saudi Arabia

Intradialytic Parenteral Nutrition in Hemodialysis Patients. Hamdy Amin, Pharm.D., MBA, BCNSP Riyadh, Saudi Arabia Intradialytic Parenteral Nutrition in Hemodialysis Patients Hamdy Amin, Pharm.D., MBA, BCNSP Riyadh, Saudi Arabia Disclosure Information Intradialytic Parenteral Nutrition in Hemodialysis Patients Hamdy

More information

NICE guideline Published: 6 July 2016 nice.org.uk/guidance/ng49

NICE guideline Published: 6 July 2016 nice.org.uk/guidance/ng49 Non-alcoholic fatty liver disease (NAFLD): assessment and management NICE guideline Published: 6 July 20 nice.org.uk/guidance/ng49 NICE 2017. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).

More information

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg

Viral Hepatitis The Preventive Potential of Antiviral Therapy. Thomas Berg Viral Hepatitis The Preventive Potential of Antiviral Therapy Thomas Berg Therapeutic and preventive strategies in patients with hepatitis virus infection Treatment of acute infection Treatment of chronic

More information

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic

Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Non-Alcoholic Fatty Liver Diseasean underestimated epidemic Amir Shlomai MD,PhD Head, Department of Medicine D The Liver Institute Rabin Medical Center, Beilinson Hospital The IASLD semi-annual meeting-

More information

Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT

Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone ABSTRACT 20 Original Article Adrenal Insufficiency in Patients with Liver Cirrhosis and Severe Sepsis: Effect on Survival after Treatment with Hydrocortisone Pattanasirigool C Prasongsuksan C Settasin S Letrochawalit

More information

MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS

MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS MANAGING END STAGE LIVER DISEASE IN RESOURCE LIMITED SETTINGS Mark W. Sonderup Division of Hepatology and Liver Laboratory Department of Medicine University of Cape Town & Groote Schuur Hospital Cirrhosis..

More information

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT

MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT MANAGEMENT OF LIVER CIRRHOSIS: PRACTICE ESSENTIALS AND PATIENT SELF-MANAGEMENT Sherona Bau, ACNP The Pfleger Liver Institute 200 UCLA Medical Plaza, Suite 214 Los Angeles, CA 90095 September 30, 2017 I

More information

The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008

The Management of Ascites & Hepatorenal Syndrome. Florence Wong University of Toronto. Falk Symposium March 14, 2008 The Management of Ascites & Hepatorenal Syndrome Florence Wong University of Toronto Falk Symposium March 14, 2008 Management of Ascites Sodium Restriction Mandatory at all stages of ascites in order to

More information

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes

European. Young Hepatologists Workshop. Organized by : Quantification of fibrosis and cirrhosis outcomes supported by from Gilea Quantification of fibrosis and cirrhosis outcomes th 5 European 5 European Young Hepatologists Workshop Young Hepatologists Workshop August, 27-29. 2015, Moulin de Vernègues Vincenza

More information

Management of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy

Management of Ascites and Hepatorenal Syndrome. Florence Wong University of Toronto. June 4, /16/ Gore & Associates: Consultancy Management of Ascites and Hepatorenal Syndrome Florence Wong University of Toronto June 4, 2016 6/16/2016 1 Disclosures Gore & Associates: Consultancy Sequana Medical: Research Funding Mallinckrodt Pharmaceutical:

More information

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow

Hepatocytes produce. Proteins Clotting factors Hormones. Bile Flow R.J.Bailey MD Hepatocytes produce Proteins Clotting factors Hormones Bile Flow Trouble.. for the liver! Trouble for the Liver Liver Gall Bladder Common Alcohol Hep C Fatty Liver Cancer Drugs Viruses Uncommon

More information

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008

National Horizon Scanning Centre. Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis. June 2008 Enhanced Liver Fibrosis Test (ELF) for evaluating liver fibrosis June 2008 This technology summary is based on information available at the time of research and a limited literature search. It is not intended

More information

Abnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital

Abnormal LFTs in migrant populations. Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital Abnormal LFTs in migrant populations Dr Doug Macdonald Consultant Hepatologist Royal Free Hospital www.migrationobservatory.ox.ac.uk Migrants in London Migrants in London Migrants in London Common liver

More information

4/26/2017. Liver Transplant and Palliative Care: Teaming up to improve care

4/26/2017. Liver Transplant and Palliative Care: Teaming up to improve care Liver Transplant and Palliative Care: Teaming up to improve care Jody C. Olson, M.D., FACP Assistant Professor of Medicine and Surgery Hepatology and Critical Care Medicine All patients with end-stage

More information

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for:

Contraindications. Indications. Complications. Currently TIPS is considered second or third line therapy for: Contraindications Absolute Relative Primary prevention variceal bleeding HCC if centrally located Active congestive heart failure Obstruction all hepatic veins Thomas D. Boyer, M.D. University of Arizona

More information

Evaluation of Renal Profile in Liver Cirrhosis Patients: A Clinical Study

Evaluation of Renal Profile in Liver Cirrhosis Patients: A Clinical Study Original article: Evaluation of Renal Profile in Liver Cirrhosis Patients: A Clinical Study Mukesh Agarwal Assistant Professor, Department of General Medicine, Teerthanker Mahaveer Medical College & Research

More information

The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio

The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist. K V Speeg, MD, PhD UT Health San Antonio The Continuum of Care for Advanced Liver Disease: Partnering with the Liver Specialist K V Speeg, MD, PhD UT Health San Antonio Objectives Review staging of liver disease Review consequences of end-stage

More information

Study On Ascitic Fluid Complement3 Level In Cirrhotic Patients With Spontaneous Bacterial Peritonitis And Without Spontaneous Bacterial Peritonitis

Study On Ascitic Fluid Complement3 Level In Cirrhotic Patients With Spontaneous Bacterial Peritonitis And Without Spontaneous Bacterial Peritonitis ISPUB.COM The Internet Journal of Gastroenterology Volume 6 Number 1 Study On Ascitic Fluid Complement3 Level In Cirrhotic Patients With Spontaneous Bacterial Peritonitis And Without Spontaneous Bacterial

More information

World Health Organization. Western Pacific Region

World Health Organization. Western Pacific Region Basic modules for hepatitis 1 Basic Module 1 Liver anatomy and physiology 2 Position of liver Midline Located in right upper abdomen Protected by the right rib cage Right upper Measures: 12 15 cm in vertical

More information

Renal Care and Liver Disease: Disease Trajectory and Hospice Eligibility

Renal Care and Liver Disease: Disease Trajectory and Hospice Eligibility Renal Care and Liver Disease: Disease Trajectory and Hospice Eligibility Terri L. Maxwell PhD, APRN VP, Strategic Initiatives Weatherbee Resources/HEN Course Materials & Disclosure Course materials including

More information

HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management

HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management HEPATOrenal Syndrome Type I: Correct Diagnosis = Correct Management Stephen G. M. Wong BSc, BSc(Med), MD, MHSc, FRCPC Associate Professor of Medicine Director, Hepatology Education Section of Hepatology

More information

Alcohol-Related Liver Disease

Alcohol-Related Liver Disease Alcohol-Related Liver Disease Nonalcoholic Fatty Liver Disease (NAFLD) 1 Why is the liver important? Your liver is a vital organ that performs many essential functions. It filters out harmful substances

More information

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology

NAFLD/NASH. Definitions. Pathology NASH. Vicki Shah PA-C, MMS Rush University Hepatology NAFLD/NASH Vicki Shah PA-C, MMS Rush University Hepatology Definitions NAFLD Evidence of hepatic steatosis by histology (5%) or imaging No causes for secondary fat accumulation EtOH, Drugs, hereditary

More information

American Journal of Oral Medicine and Radiology

American Journal of Oral Medicine and Radiology American Journal of Oral Medicine and Radiology e - ISSN - XXXX-XXXX ISSN - 2394-7721 Journal homepage: www.mcmed.us/journal/ajomr PREVALENCE OF NONALCOHOLIC FATTY LIVER DISEASE AMONG TYPE 2 DIABETIC POPULATION

More information

Liver Transplantation Evaluation: Objectives

Liver Transplantation Evaluation: Objectives Liver Transplantation Evaluation: Essential Work-Up Curtis K. Argo, MD, MS VGS/ACG Regional Postgraduate Course Williamsburg, VA September 13, 2015 Objectives Discuss determining readiness for transplantation

More information

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014

Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Prognosis of NASH VII Workshop Intenracional de Actualizaçao em Hepatologia, Aug 29th 2014 Vlad Ratziu, Université Pierre et Marie Curie, Hôpital Pitié Salpêtrière, Paris, France NASH : a severe hepatic

More information

Study of incidence and Etiology of Intestinal Obstruction

Study of incidence and Etiology of Intestinal Obstruction Original Research article: Study of incidence and Etiology of Intestinal Obstruction 1 Dr. Trupti tonape *, 2 Dr. Kedar Gorad 1 Assistant Professor, Department of Surgery, P.Dr DY Patil Medical College,

More information

Effects of Liver Disease on Pharmacokinetics

Effects of Liver Disease on Pharmacokinetics Effects of Liver Disease on Pharmacokinetics Juan J.L. Lertora, M.D., Ph.D. Director Clinical Pharmacology Program October 31, 2013 National Institutes of Health Clinical Center 1 GOALS of Effects of Liver

More information